HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.

AbstractOBJECTIVES:
The purpose of this study was to assess the clinical activity and toxicity of weekly topotecan in a large cohort of epithelial ovarian (EOC), primary peritoneal (PPC), and tubal cancer patients.
METHODS:
Records of patients with recurrent EOC, PPC, and tubal cancer who were treated with weekly topotecan (4.0 mg/m on days 1, 8, and 15 on a 28-day cycle) after failure of more than 1 prior regimen were retrospectively reviewed in 8 centers in Israel.
RESULTS:
Two hundred four patients were evaluated for efficacy and toxicity. Median age was 62 years (range, 27-89 years); 121 (59.3%) were platinum sensitive. Patients were exposed to a median of 2 previous lines (range, 1-9), and 48.5% received only 1 prior chemotherapy regimen. Median follow-up was 15.5 months (range, 2.5-112 months). Overall response rate was 26.5%, of which 11 patients (5.4%) had complete response, and 43 patients (21.1%) had partial response. Clinical benefit rate (complete response + partial response + stable disease) was 65.7%. Median progression-free survival was 4.0 months (95% confidence interval [CI], 3.5-4.5 months). There was no significant difference between platinum-sensitive and platinum-resistant patients regarding response rate or progression-free survival. Median overall survival from disease diagnosis was 45.0 months (95% CI, 40.04-49.6 months) and 16.0 months (95% CI, 12.3-19.7 months) from initiation of topotecan therapy. Overall survival was significantly different between patients with platinum-sensitive and platinum-resistant disease (19.9 vs. 10.8 months, respectively, P = 0.003; 95% CI, 8.1-16.3 months). Multivariate analysis showed that only platinum sensitivity and topotecan line were associated with overall survival. Weekly topotecan was well tolerated-with only 16.7% of patients experiencing grade 3 to 4 hematologic toxicities. There were no other grade 4 toxicities, and only 6.9% grade 3 toxicities.
CONCLUSIONS:
In this large cohort of recurrent EOC, PPC, and tubal cancer, weekly topotecan was well tolerated with good clinical benefit rate, comparable to previous studies.
AuthorsTamar Safra, Tara Berman, Adelya Yachnin, Ilan Bruchim, Mihai Meirovitz, Frida Barak, Ilan Atlas, Tally Levy, Ora Solange Rosengarten
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) Vol. 23 Issue 3 Pg. 475-80 (Mar 2013) ISSN: 1525-1438 [Electronic] United States
PMID23435437 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • Topoisomerase I Inhibitors
  • Topotecan
Topics
  • Adenocarcinoma, Mucinous (drug therapy, mortality, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Cystadenocarcinoma, Serous (drug therapy, mortality, pathology)
  • Drug Resistance, Neoplasm (drug effects)
  • Endometrial Neoplasms (drug therapy, mortality, pathology)
  • Fallopian Tube Neoplasms (drug therapy, mortality, pathology)
  • Female
  • Follow-Up Studies
  • Humans
  • Israel
  • Maximum Tolerated Dose
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local (drug therapy, mortality, pathology)
  • Neoplasm Staging
  • Ovarian Neoplasms (drug therapy, mortality, pathology)
  • Peritoneal Neoplasms (drug therapy, mortality, pathology)
  • Prognosis
  • Retrospective Studies
  • Salvage Therapy
  • Survival Rate
  • Topoisomerase I Inhibitors (therapeutic use)
  • Topotecan (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: